PDS Biotechnology grants John Andrew Dawson 22,700 options

The award vests in three equal annual installments beginning on the grant's first anniversary, subject to continued service.

Rhea-AI Filing Summary

PDS Biotechnology Corp director John Andrew Dawson received 22,700 stock options to buy common stock on October 18, 2026, at an exercise price of $1.13 per share. The options vest in three equal annual installments beginning on the first anniversary of the grant, subject to his continued service. His reported resulting position was 22,700 options.

Insider Trade Summary

Grant/Award: 22,700 shares

Grant/Award 1 txn

Insider Dawson John Andrew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	22,700	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 22,700 contracts (Direct)

Footnotes (1)

1. F1. The Stock Option shall vest in three (3) equal annual installments beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such dates.

Key Figures

Stock options granted: 22,700 options Exercise price: $1.13 per share Underlying common shares: 22,700 shares +2 more

5 metrics

Stock options granted 22,700 options Granted October 18, 2026; reported resulting position was 22,700 options

Exercise price $1.13 per share Price to exercise the option

Underlying common shares 22,700 shares Shares the options cover

Vesting schedule 3 equal annual installments Begins on the first anniversary of the grant, subject to continued service

Option expiration October 18, 2036 Expiration date of the granted options

Key Terms

Stock Option (Right to Buy), exercise price, annual installments, continued service

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"exercise price of $1.13 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual installments financial

"vest in three (3) equal annual installments"

continued service financial

"continued service to the Issuer through such dates"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did PDSB director John Andrew Dawson receive?

John Andrew Dawson, a director of PDS Biotechnology Corp, was granted 22,700 stock options on October 18, 2026, with an exercise price of $1.13 per share.

When do PDSB director John Andrew Dawson's stock options expire?

The options granted to John Andrew Dawson expire on October 18, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 06:42 PM EDT Accepted by SEC EDGAR 10/21/2026 - 06:41 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dawson John Andrew

(Last) (First) (Middle)

C/O PDS BIOTECHNOLOGY CORPORATION

303A COLLEGE ROAD EAST

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PDS Biotechnology Corp [ PDSB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.13	10/18/2026		A		22,700		(1)	10/18/2036	Common Stock	22,700	$0.00	22,700	D

Explanation of Responses:

1. The Stock Option shall vest in three (3) equal annual installments beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such dates.

	/s/ John Andrew Dawson	10/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)